Compare ASTRAZENECA PHARMA with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs AJANTA PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA AJANTA PHARMA ASTRAZENECA PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 84.5 27.1 312.1% View Chart
P/BV x 25.6 4.7 549.2% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ASTRAZENECA PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
AJANTA PHARMA
Mar-19
ASTRAZENECA PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2781,422 89.9%   
Low Rs883898 98.3%   
Sales per share (Unadj.) Rs228.4233.5 97.8%  
Earnings per share (Unadj.) Rs10.444.0 23.6%  
Cash flow per share (Unadj.) Rs16.352.2 31.2%  
Dividends per share (Unadj.) Rs09.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs98.8255.1 38.7%  
Shares outstanding (eoy) m25.0088.02 28.4%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.75.0 95.2%   
Avg P/E ratio x104.226.4 395.1%  
P/CF ratio (eoy) x66.422.2 298.8%  
Price / Book Value ratio x10.94.5 240.6%  
Dividend payout %020.5 0.0%   
Avg Mkt Cap Rs m27,008102,081 26.5%   
No. of employees `0001.46.8 19.9%   
Total wages/salary Rs m1,5354,307 35.6%   
Avg. sales/employee Rs Th4,210.93,022.6 139.3%   
Avg. wages/employee Rs Th1,132.2633.4 178.8%   
Avg. net profit/employee Rs Th191.1569.1 33.6%   
INCOME DATA
Net Sales Rs m5,71020,554 27.8%  
Other income Rs m123211 58.1%   
Total revenues Rs m5,83320,765 28.1%   
Gross profit Rs m4635,664 8.2%  
Depreciation Rs m147721 20.4%   
Interest Rs m012 0.0%   
Profit before tax Rs m4385,143 8.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,273 14.1%   
Profit after tax Rs m2593,870 6.7%  
Gross profit margin %8.127.6 29.4%  
Effective tax rate %40.824.8 165.0%   
Net profit margin %4.518.8 24.1%  
BALANCE SHEET DATA
Current assets Rs m3,20911,812 27.2%   
Current liabilities Rs m2,0703,776 54.8%   
Net working cap to sales %20.039.1 51.1%  
Current ratio x1.63.1 49.6%  
Inventory Days Days7277 93.5%  
Debtors Days Days3582 42.8%  
Net fixed assets Rs m79014,398 5.5%   
Share capital Rs m50175 28.5%   
"Free" reserves Rs m2,41922,277 10.9%   
Net worth Rs m2,46922,452 11.0%   
Long term debt Rs m07 0.0%   
Total assets Rs m4,60526,962 17.1%  
Interest coverage xNM444.3-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.8 162.6%   
Return on assets %5.614.4 39.1%  
Return on equity %10.517.2 60.9%  
Return on capital %17.723.0 77.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30010,682 2.8%   
Fx outflow Rs m2,0152,102 95.9%   
Net fx Rs m-1,7158,580 -20.0%   
CASH FLOW
From Operations Rs m883,748 2.3%  
From Investments Rs m-94-2,228 4.2%  
From Financial Activity Rs mNA-1,475 0.0%  
Net Cashflow Rs m-645 -12.6%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 1.6 19.4%  
FIIs % 15.7 7.6 206.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.0 53.5%  
Shareholders   12,856 20,968 61.3%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   BIOCON   WOCKHARDT  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 208 Points Lower; Oil & Gas and Metal Stocks Witness Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day on a negative note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

Your Safe Income Options for 2020(Fast Profits Daily)

Jan 9, 2020

What are you safest investing options in 2020 when interest rates fall.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

What the Infosys Results Tell Us About the Next Infosys(The 5 Minute Wrapup)

Jan 15, 2020

If you're interested in the next Infosys, I'll tell you where to look.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 22, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS